Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 388.10K | -2.19M | 250.35M | -1.05M | 277.90K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 156.40K | 145.60K | 62.50K | 54.50K | 42.20K |
| Total Other Non-Cash Items | -819.60K | 1.82M | -250.92M | 508.80K | -551.60K |
| Change in Net Operating Assets | 182.80K | -111.20K | -275.10K | 177.10K | 105.40K |
| Cash from Operations | -92.20K | -342.20K | -783.00K | -307.00K | -126.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 190.90K | 367.00K | 462.90K | 628.00K | 135.00K |
| Total Debt Repaid | 50.00K | -50.00K | -- | -- | -- |
| Issuance of Common Stock | 6.60K | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -33.00K | -- | -- | -- | -- |
| Cash from Financing | 214.60K | 317.00K | 462.90K | 628.00K | 135.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 122.40K | -25.20K | -320.10K | 321.00K | 8.80K |